Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

Table 2

Characteristics of included studies of leukemia in IBD.

(a)

Author

Journal

Publication year

Study design

Study population

Region of origin

Number of sites

Study duration (yrs)

Person-years

Number of patients

Diagnosis

Mean age (yrs)

Female (%)

Mean disease duration (yrs)

Surgery (%)

Bernstein et al. [24]

Cancer

2001

Case-control

Administrative claims

Canada

Regionwide

14

41,005; 21,340; 19,665

5,529; 2,857; 2,672

IBD; CD; UC

39.0; 36.3; 41.7

54.5; 59.0; 50.0

Fraser et al. [18]

Aliment Pharmacol Ther

2002

Cohort

Referral center

Europe (Western)

Countrywide

35

55,388

1,578

IBD

35.0

53.0

Jess et al. [8]

Am J Gastroenterol

2013

Cohort

Regional registry

Europe (Western)

1

32

33,843; 11,261; 22,582

2,211; 774; 1,437

IBD; CD; UC

53.0; 57.0; 49.0

Jess et al. [39]

Aliment Pharmacol Ther

2004

Cohort

Regional registry

Europe (Western)

Regionwide

35

6,569

374

CD

58.0

Lopez et al. [23]

Clin Gastroenterol Hepatol

2014

Cohort

National registry

Europe (Western)

Countrywide

3

23,457

10,810

IBD

40.0

53.0

Mellemkjær et al. [33]

Cancer Causes Control

2000

Cohort

National registry

Europe (Western)

Countrywide

16

22,875

2,645

CD

50.0

Mizushima et al. [21]

Digestion

2010

Cohort

Referral center

Asia

1

20

4,248

294

CD

39.0

30.6

Palli et al. [22]

Gastroenterology

2000

Cohort

Regional registry

Europe (Western)

1

19

10,592; 2,716; 7,877

920; 231; 689

IBD; CD; UC

Winther et al. [19]

Clin Gastroenterol Hepatol

2004

Cohort

Regional registry

Europe (Western)

Regionwide

35

22,290

1,160

UC

53.4

Yano et al. [14]

J Gastroenterol Hepatol

2013

Cohort

Referral center

Asia

1

25

10,552

770

CD

25.1

31.3

13.1

(b)

Author	Journal	Publication year	PSC (%)	Pancolitis (%)	Immunomodulator use (%)	Biologic use (%)	Observed number of leukemia cases	Incidence rate (per 100,000 persons)	Standard error	95% CI lower bound	95% CI upper bound	Bias rating
Bernstein et al. [24]	Cancer	2001			0.0; 0.0; 0.0	0.0; 0.0; 0.0	7; 3; 4	17.1; 14.1; 20.3	6.5; 8.1; 10.2	4.4; −1.9; 0.4	29.8; 30.1; 40.2	Moderate
Fraser et al. [18]	Aliment Pharmacol Ther	2002		30.0	0.0	0.0	1	1.81	1.8	−1.7	5.4	Moderate
Jess et al. [8]	Am J Gastroenterol	2013		26.7; 41.0; 19.0	27.2; 45.0; 18.0		6; 1; 5	17.7; 8.9; 22.1	7.2; 8.9; 9.9	3.5; −8.5; 2.7	31.9; 26.3; 41.5	Moderate
Jess et al. [39]	Aliment Pharmacol Ther	2004					1	15.2	15.2	−14.6	45.1	Moderate
Lopez et al. [23]	Clin Gastroenterol Hepatol	2014			0.0	0.0	0.5	2.13	3.0	−3.8	8.0	Moderate
Mellemkjær et al. [33]	Cancer Causes Control	2000					3	13.1	7.6	−1.7	27.9	Moderate
Mizushima et al. [21]	Digestion	2010		12.4			0	0.0		0.0	3.7	Moderate
Palli et al. [22]	Gastroenterology	2000					2; 0; 2	19.0; 0.0; 25.4	13.4; 18.0	−7.3; 0.0; −9.8	45.3; 3.7; 60.6	Moderate
Winther et al. [19]	Clin Gastroenterol Hepatol	2004		54.0			4	8.97	4.5	0.2	17.8	Moderate
Yano et al. [14]	J Gastroenterol Hepatol	2013		14.7			3	28.4	16.4	−3.7	60.5	Moderate

Did not report separate incidence measures for CD and UC.